Skip to content

    Glenmark Pharma.

    GLENMARK
    Healthcare·18 Aug 2025
    Management Summary

    Glenmark Pharma reported a modest 0.6% Y-o-Y consolidated revenue growth in Q1 FY26, reaching INR 32,644 million. While India's formulation business and Consumer Care showed strong growth, Europe and Emerging Markets faced headwinds. The company settled a US antitrust litigation for USD 37.75 million and expects EBITDA margins to stabilize at 23%+ from Q3 FY26, driven by a strategic shift towards high-margin branded products and new launches.

    Highlights

    5
    • Consolidated revenue at INR 32,644 million, up 0.6% Y-o-Y, driven by robust growth in key therapy areas in India and strong performance in Consumer Care.

    • India Formulation business grew 3.7% Y-o-Y to INR 12,399 million, outperforming the overall industry in secondary sales growth (15.1% vs IPM 8.5%).

    • India Consumer Care business recorded a strong 20% Y-o-Y growth, with Candid Powder leading its category with over 60% market share.

    • US antitrust litigation settled for USD 37.75 million, resolving a significant uncertainty.

    • Strategic focus on high-margin branded products and new launches like Tislelizumab, Zanubrutinib, Empagliflozin, and Liraglutide expected to drive future growth and margin improvement.

    Concerns

    4
    • Consolidated revenue growth was modest at 0.6% Y-o-Y, impacted by discontinuation of some tail-end brands and underperformance in the diabetes segment in India.

    • Europe business recorded a Y-o-Y decline of 4% in revenue to INR 6,678 million.

    • Emerging Markets revenue growth was flat at 0.2% Y-o-Y, affected by lower seasonal demand in some Latin American markets.

    • Monroe facility still awaiting FDA resolution for 5 observations, delaying restart of commercial manufacturing.

    What Changed2

    vs Q2 FY26

    Guidance items18 → 8 (-10)Q&A highlights6 → 8 (+2)
    Key financials

    Metrics

    5

    Periods

    2

    Headline

    3
    • Consolidated Revenue
      ₹3,264.4 Cr
      YoY+0.6%
    • Net Debt
      ₹1,500 Cr
    • Gross Debt
      ₹3,200 Cr

    Q1

    2
    • Capex
      ₹180 Cr
    • R&D Spend
      7%

    Segment breakdown

    RevenueY-o-Y Growth
    India Formulation Business₹1,239.9 Cr3.7%
    India Consumer Care20%
    North America
    Europe₹667.8 Cr
    Emerging Markets₹572.1 Cr0.2%
    Heatmap· 2 shared metrics

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹180 crores

    Debt

    Gross ₹3,200 crores · Net ₹1,500 crores

    M&A

    ISB 2001 (AbbVie partnership)

    joint venture · announced

    Guidance & targets

    6
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    23%+
    High
    Revenue
    India Business Growth (CAGR)
    10-15%
    Medium
    Product Launches
    US Filings
    1 application
    High
    Product Launches
    US Filings
    5-6 applications
    High
    R&D Spend
    R&D Expenditure
    7.5%
    High
    Working Capital
    Net Working Capital Days
    110-115 days
    Medium

    Monroe facility commercial manufacturing restart

    this year
    CurrentAwaiting FDA response on 5 observations
    TargetRestart of commercial manufacturing

    Why it matters

    Restarting Monroe is crucial for US injectable product supply and overall US business growth.

    We are hoping that this year we will restart commercial manufacturing. That's our view on Monroe.

    How to verify

    risks_and_concerns[risk='US FDA observations at Monroe facility'].management_stance

    Risks & concerns

    3
    RiskSeverity

    US FDA observations at Monroe facility

    5 observations from last inspection, responded to FDA, awaiting resolution to restart commercial manufacturing.Management acknowledged

    medium

    Ongoing US antitrust litigations

    Settled with DPPs for USD 37.75 million, but other classes are still being litigated with no clear timeline.Management acknowledged

    medium

    Underperformance in India diabetes segment

    Impacted Q1 India sales, but new launches like LIRAFIT and Empagliflozin expected to improve performance from Q2.Management acknowledged

    low

    Q&A highlights

    8

    “So I think going forward, this quarter and maybe Q2, right, from Q3 onwards we expect the secondary sales growth of India, and the reported growth will be very close, right, from then onwards.”

    Analyst questioned the drag from the antidiabetic portfolio and the divergence between secondary and reported growth. Management clarified that new launches and focus on high-margin products would align reported and secondary growth from Q3.

    asked by Damayanti Kerai

    3 min read6 chapters

    Detailed Narrative

    01

    Q1 FY26 Performance Overview

    Glenmark Pharmaceuticals reported a consolidated revenue from operations of INR 32,644 million for Q1 FY26, marking a modest Y-o-Y growth of 0.6%. The India formulation business contributed INR 12,399 million, growing 3.7% Y-o-Y, while the Consumer Care segment saw a robust 20% Y-o-Y growth. North America revenues stood at INR 7,780 million (USD 91 million), showing an 8.9% Q-o-Q growth, despite a challenging environment. Europe and Emerging Markets experienced a Y-o-Y decline of 4% and a flat growth of 0.2% respectively.

    02

    India Business Strategy and Performance

    The India business continued to outperform the overall industry in secondary sales, recording 15.1% growth in Q1 FY26 compared to the IPM's 8.5%. This growth was robust across cardiac, respiratory, and dermatology therapy areas. Management indicated that the reported growth was impacted by the discontinuation of some tail-end brands and underperformance in the diabetes segment. However, with new launches like Tislelizumab, Zanubrutinib, and Empagliflozin, and full supply of Liraglutide, the company expects reported growth to align with secondary sales from Q3 FY26 onwards, targeting a 10-15% CAGR over the next 3-5 years.

    03

    North America Business and Regulatory Updates

    North America revenues grew 8.9% Q-o-Q to USD 91 million, driven by injectable product launches and partnered products. Glenmark plans to file 1 application in the next quarter and 5-6 for the full year. The company settled a multi-district antitrust litigation for USD 37.75 million, while denying all allegations. The Monroe facility, which received 5 FDA observations, has responded, and the company hopes to restart commercial manufacturing this year, pending FDA resolution.

    04

    Global Markets Performance and Outlook

    Europe's revenue declined 4% Y-o-Y to INR 6,678 million, but management anticipates a return to double-digit growth from Q2 FY26 onwards. Emerging Markets saw flat Y-o-Y growth at INR 5,721 million, primarily due to lower seasonal demand in Latin America, but is expected to achieve double-digit growth on a constant currency basis for FY26. Key brands like RYALTRIS continue to perform well globally, with marketing applications in over 90 countries and commercialization in over 45 markets.

    05

    IGI Oncology Pipeline and AbbVie Partnership

    IGI (Glenmark's innovation arm) presented promising Phase 1 results for ISB 2001 in relapsed/refractory multiple myeloma, showing a 79% overall response rate. The landmark partnership with AbbVie for ISB 2001 grants AbbVie global rights (excluding emerging markets) and validates IGI's platform technology. The upfront payment from AbbVie, expected to be booked in Q2 FY26, will cover IGI's expenditure for the next 3 years (estimated at $210-225 million) and is projected to make Glenmark cash positive on a consolidated basis.

    06

    Capital Allocation and Financial Guidance

    Net debt at the end of Q1 FY26 stood at INR 1,500 crores, with gross debt at INR 3,200 crores. Capital expenditure for the quarter was INR 180 crores, with the full-year guidance remaining on track. R&D expenditure for Q1 was around 7% of revenue, with half related to IGI. Management guided for EBITDA margins to stabilize at 23%+ from Q3 FY26 onwards, driven by the strategic focus on high-margin branded products and a diversified geographical portfolio. Net working capital days are targeted to be maintained at 110-115 days.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.